Agenus Inc News and Q2 Results for 201
Agenus (AGEN) announced results with better than usual news including the following: 

• $200 million received from BMS for anti-TIGIT bispecific antibody collaboration
• FDA cleared IND for AGEN1777 clinical enrollment
• AGEN1181 rapidly advancing in the clinic - data to be presented in 2H 2021
• Cell therapy . . .
  
  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Today’s Highlights

  Agenus (AGEN), Intellia Therapeutics (NTLA)

  August 9, 2021
  Tweet Pin It